NovoCure News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.03.24	Why NovoCure Stock Soared 18.3% This Week (MotleyFool)
28.03.24	Why Novocure Stock Is Jumping Today (MotleyFool)
27.03.24	Peeling Back The Layers: Exploring NovoCure Through Analyst Insights (Benzinga)
27.03.24	Novocure Shares Rise After Phase 3 METIS Trial Met Primary Endpoint (RTTNews)
27.03.24	Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows (Benzinga)
11.03.24	INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO (Businesswire)
22.02.24	NovoCure (NVCR) Q4 2023 Earnings Call Transcript (MotleyFool)
22.02.24	Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update (Businesswire)
21.02.24	Ausblick: NovoCure gewährt Anlegern Blick in die Bücher (finanzen.net)
07.02.24	Erste Schätzungen: NovoCure präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
18.01.24	Why Is Cancer Focused Novocure Stock Trading Higher Today? (Benzinga)
18.01.24	NovoCure Surges Over FDA Acceptance Of The PMA Application For TTFields Therapy (RTTNews)
18.01.24	Fastenal Posts Upbeat Earnings, Joins NovoCure, Taiwan Semiconductor Manufacturing And Other Big Stocks Moving Higher On Thursday (Benzinga)
18.01.24	Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer (Businesswire)
09.01.24	Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma (Businesswire)
08.01.24	Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update (Businesswire)
04.01.24	Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer (Businesswire)
27.12.23	Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference (Businesswire)
28.11.23	Novocure To Reduce 13% Of Current Workforce - Quick Facts (RTTNews)
28.11.23	Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability (Businesswire)
21.11.23	Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference (Businesswire)
10.11.23	Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting (Businesswire)
26.10.23	Novocure Reports Third Quarter 2023 Financial Results (Businesswire)
25.10.23	Ausblick: NovoCure öffnet die Bücher zum abgelaufenen Quartal (finanzen.net)
16.10.23	Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023 (Businesswire)
12.10.23	Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program (Businesswire)
11.10.23	Erste Schätzungen: NovoCure zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
29.09.23	Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting (Businesswire)
08.09.23	Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer (Businesswire)
30.08.23	Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies (Businesswire)
28.08.23	Novocure : Phase 3 Trial In Platinum-resistant Ovarian Cancer Fails To Meet Main Goal; Stock Plunges (RTTNews)
28.08.23	Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer (Businesswire)
25.08.23	Novocure to Participate in Upcoming Investor Conferences (Businesswire)
16.08.23	NVCR IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages NovoCure Limited Investors with Losses to Secure Counsel Before Important August 18 Deadline in Securities Class Action - NVCR (PR Newswire)
10.08.23	NVCR DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important August 18 Deadline in Securities Class Action - NVCR (PR Newswire)
03.08.23	ROSEN, A LONGSTANDING LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important August 18 Deadline in Securities Class Action - NVCR (PR Newswire)
27.07.23	NVCR NOTICE: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
27.07.23	Novocure Reports Second Quarter 2023 Financial Results (Businesswire)
26.07.23	Ausblick: NovoCure vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
21.07.23	Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer (Businesswire)
18.07.23	ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
12.07.23	Erste Schätzungen: NovoCure legt Zahlen zum jüngsten Quartal vor (finanzen.net)
08.07.23	ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR (PR Newswire)
03.07.23	Novocure to Report Second Quarter 2023 Financial Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu NovoCure Limited

Aktien Top/Flop

Meistgelesene Nachrichten